The deal includes a $45 million upfront payment and R&D work in up to five undisclosed infectious disease targets.
Luc Debruyne, who has served as GlaxoSmithKline's president of vaccines for five years, will leave the company at the end of the year.
GSK and Merck will still lead as the top vaccine makers in 2024, according to a new report, while Sanofi and Pfizer are expected to swap positions.
Emergent BioSolutions, which last year picked up a plant from Sanofi that makes smallpox, is now expanding a fill-finish facility.
Looking to take on global vaccine heavyweights, SutroVax revs up with Series C funding and a prominent new chairman.
A new study showed Ocrevus could reduce patients' immune responses to vaccines against tetanus, seasonal flu and pneumococcus.
Sanofi raised the price of Flublok by 12.5% last year, its only increase above the U.S. National Health Expenditure growth rate.
Here is some other vaccine news of note for the week.
In the early stages of its Shingrix rollout, GlaxoSmithKline boosted efforts to help doctors educate themselves about the vaccine.
The chairman of Zhifei Biological Products, which holds Chinese rights to Gardasil and Gardasil 9, boasted a net worth of about $4.6 billion Wednesday.